Liquid to Solid Transitions in Biomolecular Condensates

16 concepts10 papers1 proposal

Cells use a process called liquid-liquid phase separation (LLPS) to organize their internal machinery without the need for physical membranes. Much like oil droplets separating from water, specific proteins and RNAs spontaneously condense into dynamic, fluid compartments known as biomolecular condensates. These droplets serve vital cellular functions, concentrating molecules to accelerate biochemical reactions or protect sensitive components during stress.

However, as reviewed by Lin Zhang et al. in Phase-Separated Subcellular Compartmentation and Related Human Diseases, this elegant organizational strategy harbors a dangerous physical vulnerability. Because condensates drastically concentrate proteins, they act as thermodynamic ticking time bombs. Over time, or under the influence of genetic mutations, these dynamic liquid droplets can undergo an aberrant "liquid-to-solid" phase transition, hardening into irreversible gels, rigid hydrogels, or highly ordered amyloid fibrils associated with devastating neurodegenerative diseases.

The Physics of the Crowded Droplet

To understand why a functional liquid droplet solidifies, we must look at the microscopic forces driving phase separation. In a healthy state, proteins within a condensate interact via weak, transient, and multivalent bonds. The molecules are highly concentrated but remain free to move, constantly swapping interaction partners to maintain a fluid, dynamic state.

However, a condensate is an environment of extreme molecular crowding and high internal viscosity. As detailed by Ying Huai et al. in How do RNA binding proteins trigger liquid-liquid phase separation in human health and diseases?, if these droplets persist for too long without being disassembled, the transient interactions can slowly mature into permanent, rigid structures.

The physical intuition behind this transition lies in the kinetic barrier to protein aggregation. In a dilute cellular solution, the probability of multiple protein molecules colliding in the exact orientation required to seed an amyloid fibril—a process called primary nucleation—is exceptionally low. Inside a phase-separated droplet, however, the local concentration of these proteins increases by orders of magnitude. By forcing these molecules into close, prolonged proximity, the droplet lowers the entropic penalty of aggregation. As a result, the dense liquid environment of the condensate effectively acts as a crucible that accelerates structural reorganization into solid aggregates, a challenge highlighted by Samuel Dada et al. in Pharmacological inhibition of α-synuclein aggregation within liquid condensates.

Mapping the Nanoscale Aging Process

Because these transitions occur inside sub-micron droplets, tracking the exact molecular triggers has historically been a massive experimental challenge. How do we observe a flexible protein network as it slowly locks into a rigid solid?

To peer inside this "aging" process, researchers have turned to advanced biophysical toolkits. Francesco Simone Ruggeri et al. established a protocol using nanoscale infrared vibrational spectroscopy (AFM-IR) in Unraveling the Physicochemical Determinants of Protein Liquid-liquid Phase Separation by Nanoscale Infrared Vibrational Spectroscopy. This technique allows scientists to simultaneously map the morphology, mechanical stiffness, and chemical structure of individual droplets at the nanometer scale.

Using these nanoscale profiling tools, Alyssa Miller et al. tracked the evolution of intermolecular interactions in Nanoscale profiling of evolving intermolecular interactions in ageing FUS condensates. The authors captured the precise intermediate states of the transition, demonstrating how the gradual accumulation of rigid chemical bonds over hours or days shifts the macroscopic property of the condensate from a flexible liquid to an inflexible, pathological solid.

Triggers of Pathological Maturation

What tilts the balance from functional fluidity to irreversible solidification? The research points to two primary drivers: genetic mutations and cross-protein interactions.

Genetic Mutations

Certain proteins, such as FUS and TDP-43, contain intrinsically disordered regions (IDRs) that are highly prone to phase separation. Tetsuro Murakami et al. demonstrated in ALS/FTD Mutation-Induced Phase Transition of FUS Liquid Droplets and Reversible Hydrogels into Irreversible Hydrogels Impairs RNP Granule Function that disease-linked mutations in the FUS protein alter its biophysical properties. These mutations act like "sticky tape," strengthening the intermolecular bonds and driving a rapid, aberrant transition from dynamic droplets into stable, irreversible hydrogels. These hardened structures physically trap essential cellular components, disrupting vital processes like RNA granule function and causing cellular toxicity.

Cross-Protein Seeding

Condensates are rarely composed of a single protein species, and the presence of other proteins can drastically alter the phase landscape. In Amyloid-β modulates the phase separation and aggregation of α-synuclein, Alexander Röntgen et al. discovered that amyloid-beta (Aβ) peptides directly modulate the behavior of $\alpha$-synuclein condensates. Interestingly, different variants of the same peptide use different mechanisms: Aβ42 acts as a physical surface nucleation site that triggers $\alpha$-synuclein condensation, while Aβ40 integrates directly inside the droplets, accelerating their internal maturation into solid fibrils.

The Toxicity Paradox: Droplets vs. Fibrils

Intuitively, one might assume that the final, highly ordered solid fibril is the most toxic species in the cell. However, recent insights reveal a more complex "toxicity paradox" where the intermediate states of the liquid-to-solid transition are often the most damaging.

Consider the findings of Rodrigo Cataldi et al. in A dopamine metabolite stabilizes neurotoxic amyloid-β oligomers. The authors found that a reactive dopamine metabolite (DOPAL) can arrest the aggregation process of Aβ midway. By preventing these proteins from completing their transition into large, insoluble, and relatively inert fibrils, DOPAL stabilizes highly reactive, small-scale oligomeric intermediates that cause severe neurotoxicity.

This concept is further supported by Attila Horváth et al. in Sequence-based Prediction of the Cellular Toxicity Associated with Amyloid Aggregation within Protein Condensates. The authors discovered that mutations promoting rapid amyloid aggregation can actually decrease cellular toxicity, likely because they quickly sequester dangerous, reactive protein species into stable structures. Conversely, mutations that favor prolonged, aging droplet states increase toxicity. The prolonged "aging droplet" state allows for a chaotic mix of aberrant interactions that disrupt cellular homeostasis far more than a completed solid crystal.

[ Dynamic Liquid Droplet ]  <-- Functional, reversible state
           │
           ▼
[ Prolonged Aging Droplet ] <-- HIGH TOXICITY (Chaotic, reactive intermediates)
           │
           ├────────────────────────┐
           ▼                        ▼
[ Irreversible Solid Fibril ]   [ Non-Toxic Gelation ]
(Sequestration of species)      (Steered by Chaperones like DNAJB6)

Crucially, cells have evolved protective mechanisms to safely navigate this physical landscape. Samuel J. Resnick et al. demonstrated in Multiplex neurodegeneration proteotoxicity platform reveals DNAJB6 promotes non-toxic FUS condensate gelation and inhibits neurotoxicity that the molecular chaperone DNAJB6 can intervene in the maturation process. Instead of allowing FUS condensates to mature into destructive amyloid fibrils, DNAJB6 promotes an alternative, non-toxic gelled state, neutralizing the protein's toxicity without requiring the disassembly of the condensate.

Therapeutic Interventions

Understanding that pathological aggregation occurs within a phase-separated liquid environment fundamentally changes how we design therapeutics. Rather than trying to dissolve massive, fully formed solid plaques, a more effective strategy is to target the liquid state to prevent primary nucleation from ever occurring.

The authors of Pharmacological inhibition of α-synuclein aggregation within liquid condensates demonstrated the viability of this approach using a small molecule called claramine. Claramine specifically partitions into $\alpha$-synuclein condensates and stabilizes their liquid-like state. By inhibiting primary nucleation inside the crowded droplet, the molecule prevents the initial structural shift that triggers solidification. This strategy shifts the therapeutic paradigm from "plaque-busting" to phase stabilization, offering a promising frontier for halting neurodegeneration before irreversible structural damage begins.

History & citationVersion 1 · 2026-10-04

Current · Permanent link

View frozen version 1

Cite this direction

Latest version (a living page):

@misc{lacuna_liquid_to_solid_phase_transition_4547ea54,
  title = {liquid-to-solid phase transition},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/liquid-to-solid-phase-transition/rdr_4547ea54b6324bc489dafacd998a96e5},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-21},
}

This exact version (version 1, frozen text):

@misc{lacuna_liquid_to_solid_phase_transition_4547ea54_v1,
  title = {liquid-to-solid phase transition},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/liquid-to-solid-phase-transition/rdr_4547ea54b6324bc489dafacd998a96e5/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-21},
}
About

These directions overlap with this one through shared papers.

See something wrong? Report a mistake